Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Aridis Pharmaceuticals, Inc. (ARDS)

1.1   0 (0%) 07-02 19:31
Open: 1.13 Pre. Close: 1.1
High: 1.16 Low: 1.0973
Volume: 28,264 Market Cap: 19(M)
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.16 - 1.17 1.17 - 1.18
Low: 1.08 - 1.09 1.09 - 1.1
Close: 1.09 - 1.1 1.1 - 1.11

Technical analysis

as of: 2022-07-01 4:20:06 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.71     One year: 2.04
Support: Support1: 1    Support2: 0.84
Resistance: Resistance1: 1.46    Resistance2: 1.75
Pivot: 1.32
Moving Average: MA(5): 1.14     MA(20): 1.28
MA(100): 1.47     MA(250): 2.53
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 9.3     %D(3): 12.1
RSI: RSI(14): 40
52-week: High: 7.69  Low: 0.87
Average Vol(K): 3-Month: 60 (K)  10-Days: 46 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ARDS ] has closed above bottom band by 11.2%. Bollinger Bands are 1.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 01 Jul 2022
Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing - Nasdaq

Fri, 01 Jul 2022
Acute Respiratory Distress Syndrome Secondary to Enterovirus-Human-Rhinovirus Infection in an Adult - Cureus

Wed, 29 Jun 2022
Spontaneous breathing activity in COVID-19-related lung failure - Cochrane

Wed, 29 Jun 2022
Host lung microbiota promotes malaria-associated acute respiratory distress syndrome - Nature.com

Thu, 23 Jun 2022
Outcome of post-traumatic acute respiratory distress syndrome in young patients requiring extracorporeal membrane oxygenation (ECMO) | Scientific Reports - Nature.com

Wed, 22 Jun 2022
ARDS survivors at elevated risk for insomnia 1 year after diagnosis - Healio

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 14 (M)
% Held by Insiders 1.369e+007 (%)
% Held by Institutions 18.1 (%)
Shares Short 113 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.228e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 782.4
Return on Equity (ttm) -127.4
Qtrly Rev. Growth 1.53e+006
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.53913e+008
Qtrly Earnings Growth -4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -23 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.85

Stock Dividends

Dividend 0
Forward Dividend 109450
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.